Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 7/20 | 0.46 |
| ▸ | HTR2B | P41595 | 7/20 | 0.46 |
| ▸ | HTR2A | P28223 | 6/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | PYGL | P06737 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.40 |
| ▸ | HTR7 | P34969 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1154693 | 1.00 | MAP3K14 (0.47) | MAP3K14HTR2CHTR2BHTR2ASLC6A4 | |
| SCHEMBL1155475 | 1.00 | MAP3K14 (0.47) | MAP3K14HTR2CHTR2BHTR2ASLC6A4 | |
| SCHEMBL6026462 | 0.89 | MAP3K14 (0.45) | MAP3K14HTR2CHTR2BHTR2ASLC6A4 | |
| SCHEMBL1693312 | 0.84 | MAP3K14 (0.51) | MAP3K14HTR2CHTR2BHTR2ASLC6A4 | |
| SCHEMBL29959450 | 0.84 | MAP3K14 (0.51) | MAP3K14HTR2CHTR2BHTR2ASLC6A4 | |
| SCHEMBL9281232 | 0.84 | MAP3K14 (0.51) | MAP3K14HTR2CHTR2BHTR2ASLC6A4 | |
| SCHEMBL15909359 | 0.84 | MAP3K14 (0.51) | MAP3K14HTR2CHTR2BHTR2ASLC6A4 | |
| SCHEMBL19899043 | 0.81 | HTR2C (0.44) | MAP3K14HTR2CHTR2BHTR2ASLC6A4 | |
| SCHEMBL19899047 | 0.81 | HTR2C (0.44) | MAP3K14HTR2CHTR2BHTR2ASLC6A4 | |
| SCHEMBL11327843 | 0.79 | DRD2 (0.47) | HTR2CHTR2BHTR2ASLC6A4ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021097139-A1 | CHIRAL SYNTHESIS OF A TERTIARY ALCOHOL | RECURIUM IP HOLDINGS, LLC (US) | 2021-05-20 | — | — | WO | disclosed |
| US-10913742-B2 | Oxadiazolones as transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-20190284189-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2019-09-19 | — | — | US | disclosed |
| EP-3121176-A1 | 2,4-DIAMINOQUINAZOLINES FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY | Families of Spinal Muscular Atrophy (US) | 2017-01-25 | — | — | EP | disclosed |
| EP-1765810-B1 | 2,4-DIAMINOQUINAZOLINES FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2016-08-17 | — | — | EP | disclosed |
| EP-2514748-B1 | 2,4-diaminoquinazolines for spinal muscular atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2016-08-10 | — | — | EP | disclosed |
| US-20160152577-A1 | 2,4-Diaminoquinazolines for Spinal Muscular Atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2016-06-02 | — | — | US | disclosed |
| EP-2755972-B1 | INDANYL-SUBSTITUTED 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDINES, THEIR USE AS MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | SANOFI SA (FR) | 2015-10-28 | — | — | EP | disclosed |
| US-9067897-B2 | 2,4-Diaminoquinazolines for spinal muscular atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2015-06-30 | — | — | US | disclosed |
| US-8455500-B2 | 3-hydroxy-5-arylisoxazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-06-04 | — | — | US | disclosed |
| US-20110124671-A1 | SPIROINDENES AND SPIROINDANES AS MODULATORS OF CHEMOKINE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2011-05-26 | — | — | US | disclosed |
| US-20110124671-A1 | SPIROINDENES AND SPIROINDANES AS MODULATORS OF CHEMOKINE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2011-05-26 | — | — | US | disclosed |
| US-20110112118-A1 | 2,4-Diaminoquinazolines for Spinal Muscular Atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2011-05-12 | — | — | US | disclosed |
| US-7888366-B2 | 2,4-diaminoquinazolines for spinal muscular atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2011-02-15 | — | — | US | disclosed |
| EP-2190286-A1 | SPIROINDENES AND SPIROINDANES AS MODULATORS OF CHEMOKINE RECEPTORS | Glaxo Group Limited (GB) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009023754-A1 | SPIROINDENES AND SPIROINDANES AS MODULATORS OF CHEMOKINE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009023754-A1 | SPIROINDENES AND SPIROINDANES AS MODULATORS OF CHEMOKINE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2009-02-19 | — | — | WO | disclosed |
| EP-1765810-A1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | Decode Chemistry, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2005123724-A1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | DECODE CHEMISTRY, INC. (US) | 2005-12-29 | — | — | WO | disclosed |
| US-20050288314-A1 | 2,4-diaminoquinazolines for spinal muscular atrophy | DECODE CHEMISTRY, INC. (US) | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112118-A1 | 2,4-Diaminoquinazolines for Spinal Muscular Atrophy | SMN1; SMN2, MUSK, MYO3B | MAP3K14 1487/4885HTR2C 3144/4885HTR2B 3185/4885 |
| US-20160152577-A1 | 2,4-Diaminoquinazolines for Spinal Muscular Atrophy | SMN1; SMN2, MUSK, MYO3B | MAP3K14 1487/4885HTR2C 3144/4885HTR2B 3185/4885 |
| US-20050288314-A1 | 2,4-diaminoquinazolines for spinal muscular atrophy | SMN1; SMN2, MUSK, MYO3B | MAP3K14 1487/4885HTR2C 3144/4885HTR2B 3185/4885 |
| US-20110124671-A1 | SPIROINDENES AND SPIROINDANES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR2, CXCR2, CCR5 | MAP3K14 1129/4885HTR2C 3356/4885HTR2B 2654/4885 |
| US-10913742-B2 | Oxadiazolones as transient receptor potential channel inhibitors | TRPA1, TRPV1, TRPV3 | MAP3K14 1555/4885HTR2C 316/4885HTR2B 374/4885 |
| US-20190284189-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | TRPA1, TRPV1, TRPV3 | MAP3K14 1555/4885HTR2C 316/4885HTR2B 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.